articleTop 1% cited

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

The American Journal of Gastroenterology · 2012 · Vol. 107(9) · pp. 1409–1422

Gary R. Lichtenstein✉(University of Pennsylvania)Brian G. Feagan(Western University)Russell D. Cohen(University of Chicago Medical Center)Bruce Salzberg(Atlanta Gastroenterology Associates)Robert H. Diamond(Janssen (United States))Samiyeh Price(Janssen (United States))Wayne Langholff(Johnson & Johnson (United States))Anil Londhe(Johnson & Johnson (United States))William J. Sandborn(Fundación Juan March)

View via DOI Publisher page

Abstract

Mortality was similar between infliximab- and other-treatments-only-treated CD patients. An increased risk of serious infection with infliximab was observed, although CD severity and use of prednisone or narcotic analgesics carried higher risks.

Inflammatory Bowel Disease Microscopic Colitis Immunodeficiency and Autoimmune DisordersMedicineInfliximabInternal medicineHazard ratioCrohn's diseasePrednisoneConfidence intervalInflammatory bowel diseaseSurgeryDisease

MeSH terms

InfliximabAdultAntibodies, MonoclonalCrohn DiseaseFemaleFollow-Up StudiesGastrointestinal AgentsHumansImmunosuppressive AgentsInfectionsMaleMiddle AgedPrednisoneProspective StudiesRegistries